Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metastatic Merkel cell carcinoma response to nivolumab.
Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD. Walocko FM, et al. Among authors: fecher la. J Immunother Cancer. 2016 Nov 15;4:79. doi: 10.1186/s40425-016-0186-1. eCollection 2016. J Immunother Cancer. 2016. PMID: 27879975 Free PMC article.
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab.
Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD. Walocko FM, et al. Among authors: fecher la. J Immunother Cancer. 2017 Mar 6;5:27. doi: 10.1186/s40425-017-0221-x. eCollection 2017. J Immunother Cancer. 2017. PMID: 28286652 Free PMC article.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Lin H, et al. Among authors: fecher la. J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. J Clin Invest. 2018. PMID: 29337305 Free PMC article.
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Bishu S, et al. Among authors: fecher la. Gastroenterology. 2021 Feb;160(3):932-934.e3. doi: 10.1053/j.gastro.2020.10.029. Epub 2020 Oct 21. Gastroenterology. 2021. PMID: 33096100 Free PMC article. No abstract available.
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Ma VT, Daignault-Newton S, Waninger JJ, Journey S, Chopra Z, Tezel A, Redman BG, Fecher LA, Green MD, Alva AS, Lao CD. Ma VT, et al. Among authors: fecher la. Pigment Cell Melanoma Res. 2021 May;34(3):629-640. doi: 10.1111/pcmr.12944. Epub 2020 Nov 22. Pigment Cell Melanoma Res. 2021. PMID: 33128316 Free article.
Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ, Ma VT, Journey S, Skvarce J, Chopra Z, Tezel A, Bryant AK, Mayo C, Sun Y, Sankar K, Ramnath N, Lao C, Sussman JB, Fecher L, Alva A, Green MD. Waninger JJ, et al. JAMA Netw Open. 2021 Mar 1;4(3):e210980. doi: 10.1001/jamanetworkopen.2021.0980. JAMA Netw Open. 2021. PMID: 33687443 Free PMC article.
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. LoRusso PM, et al. Among authors: fecher la. PLoS One. 2021 Apr 7;16(4):e0248097. doi: 10.1371/journal.pone.0248097. eCollection 2021. PLoS One. 2021. PMID: 33826614 Free PMC article. Clinical Trial.
72 results